Marzia Malcangio Selected Research

cathepsin S

9/2020	Cathepsin S as a potential therapeutic target for chronic pain.
1/2020	Changes in vascular permeability in the spinal cord contribute to chemotherapy-induced neuropathic pain.
4/2016	Neuron-immune mechanisms contribute to pain in early stages of arthritis.
1/2016	Selective Cathepsin S Inhibition with MIV-247 Attenuates Mechanical Allodynia and Enhances the Antiallodynic Effects of Gabapentin and Pregabalin in a Mouse Model of Neuropathic Pain.
5/2014	Monocytes expressing CX3CR1 orchestrate the development of vincristine-induced pain.
6/2012	Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model.
4/2012	Microglial signalling mechanisms: Cathepsin S and Fractalkine.
11/2010	Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor.
10/2008	Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.
9/2008	Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marzia Malcangio Research Topics

Disease

33	Pain (Aches) 01/2021 - 12/2002
22	Neuralgia (Stump Neuralgia) 01/2021 - 10/2002
21	Hyperalgesia 01/2020 - 10/2002
15	Chronic Pain 01/2021 - 10/2004
10	Hypersensitivity (Allergy) 01/2020 - 05/2002
9	Inflammation (Inflammations) 01/2017 - 10/2002
6	Peripheral Nerve Injuries 12/2019 - 02/2007
5	Neoplasms (Cancer) 01/2020 - 08/2008
3	Painful Neuropathy 01/2021 - 08/2008
3	Parkinson Disease (Parkinson's Disease) 01/2021 - 10/2004
2	Wounds and Injuries (Trauma) 01/2021 - 11/2017
2	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 10/2004
2	Arthritis (Polyarthritis) 01/2020 - 01/2016
2	Bone Neoplasms (Bone Cancer) 03/2016 - 09/2010
2	Experimental Arthritis 06/2015 - 06/2012
1	Atherosclerotic Plaque (Atheroma) 01/2017
1	Atherosclerosis 01/2017
1	Osteonecrosis (Kienbock's Disease) 01/2016
1	Osteoarthritis 06/2015
1	Migraine Disorders (Migraine) 10/2013
1	Complex Regional Pain Syndromes 10/2013

Drug/Important Bio-Agent (IBA)

12	cathepsin SIBA 09/2020 - 06/2007
10	Analgesics (Analgesic Drugs)IBA 01/2021 - 11/2004
8	Chemokine CX3CL1IBA 01/2021 - 05/2008
8	ChemokinesIBA 04/2018 - 04/2009
6	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2017 - 10/2002
5	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 08/2008
4	MicroRNAs (MicroRNA)IBA 01/2020 - 10/2013
4	Adenosine Triphosphate (ATP)IBA 01/2017 - 09/2010
4	Cysteine Proteases (Cysteine Protease)IBA 04/2012 - 06/2007
3	Reactive Oxygen Species (Oxygen Radicals)IBA 12/2019 - 01/2009
3	AnkyrinsIBA 12/2019 - 03/2011
3	CX3C Chemokine Receptor 1IBA 12/2019 - 08/2010
3	Pharmaceutical PreparationsIBA 05/2018 - 09/2013
3	Gabapentin (Neurontin)FDA LinkGeneric 01/2016 - 11/2004
3	ZymosanIBA 06/2015 - 02/2007
3	CytokinesIBA 01/2013 - 11/2006
2	Purinergic Receptors (Receptors, Purine)IBA 05/2018 - 09/2013
2	CalciumIBA 01/2017 - 09/2013
2	Peptides (Polypeptides)IBA 01/2017 - 03/2016
2	CollagenIBA 04/2016 - 06/2015
2	Calcitonin Gene-Related PeptideIBA 03/2016 - 06/2015
2	Neutralizing AntibodiesIBA 06/2012 - 06/2007
2	Opioid Analgesics (Opioids)IBA 04/2012 - 02/2003
2	Purinergic P2X7 ReceptorsIBA 11/2010 - 01/2010
2	Interleukin-1beta (Interleukin 1 beta)IBA 01/2010 - 11/2006
2	Messenger RNA (mRNA)IBA 05/2009 - 08/2007
2	Phosphotransferases (Kinase)IBA 04/2009 - 12/2002
2	Formaldehyde (Formol)FDA Link 08/2008 - 10/2002
2	p38 Mitogen-Activated Protein KinasesIBA 06/2007 - 11/2006
1	Complement System Proteins (Complement)IBA 01/2021
1	Small Cytoplasmic RNAIBA 01/2021
1	LipidsIBA 01/2020
1	PlasticsIBA 12/2019
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2019
1	rotigotine FDA Link 01/2019
1	safinamideIBA 01/2019
1	Apomorphine FDA Link 01/2019
1	Botulinum Toxins (Botulinum Toxin)IBA 01/2019
1	Levodopa (L Dopa)FDA LinkGeneric 01/2019
1	Monoamine Oxidase (MAO)IBA 01/2019
1	Naloxone (Narcan)FDA LinkGeneric 01/2019
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2019
1	Dopamine Agents (Dopaminergic Agents)IBA 01/2019
1	17- (dimethylaminoethylamino)- 17- demethoxygeldanamycinIBA 05/2018
1	AntagomirsIBA 11/2017
1	1-penicillamyl-Leu(2)- oxytocinIBA 01/2017
1	Monoclonal AntibodiesIBA 01/2017
1	Lipoproteins (Lipoprotein)IBA 01/2017
1	oxidized- L- alpha- 1- palmitoyl- 2- arachidonoyl- sn- glycero- 3- phosphorylcholineIBA 01/2017
1	Nerve Growth Factors (Neurotrophins)IBA 01/2017
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 01/2017
1	Biological ProductsIBA 01/2017
1	Phospholipids (Phosphatides)FDA LinkGeneric 01/2017
1	3- (5- (2,3- dichlorophenyl)- 1H- tetrazol- 1- yl)methylpyridineIBA 04/2016
1	LigandsIBA 01/2016
1	Freund's AdjuvantIBA 01/2016
1	CationsIBA 01/2016
1	Opiate AlkaloidsIBA 01/2016
1	Oxidoreductases (Dehydrogenase)IBA 01/2016
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 01/2016
1	Pregabalin (Lyrica)FDA Link 01/2016
1	MIV-247IBA 01/2016
1	GTP-Binding Proteins (G-Protein)IBA 06/2015
1	Acetates (Acetic Acid Esters)FDA Link 06/2015
1	Antineoplastic Agents (Antineoplastics)IBA 05/2014
1	Biomarkers (Surrogate Marker)IBA 10/2013
1	Macromolecular SubstancesIBA 10/2013
1	Collagen Type II (Type II Collagen)IBA 06/2012

Therapy/Procedure

11	Therapeutics 09/2020 - 11/2004
7	Drug Therapy (Chemotherapy) 01/2021 - 08/2008
5	Spinal Injections 01/2010 - 05/2002
4	Oral Administration 01/2016 - 08/2008
3	Injections 01/2019 - 11/2006
3	Intra-Articular Injections 01/2016 - 03/2011
2	Ligation 06/2015 - 08/2010
1	Deep Brain Stimulation 01/2019
1	Transdermal Patch 01/2019
1	Withholding Treatment 01/2017
1	Analgesia 10/2013